Sugi Predict

Sugi Predict / Compounds / SCHEMBL56372

SCHEMBL56372

SCHEMBL56372

O=[C]c1cc2ccccc2[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 1/20 0.48
▸ KDR P35968 1/20 0.48
▸ FLT3 P36888 1/20 0.48
▸ CYP2A6 P11509 1/20 0.48
▸ AOC3 Q16853 2/20 0.48
▸ KDM4E B2RXH2 5/20 0.47
▸ MAPT P10636 4/20 0.47
▸ HPGD P15428 3/20 0.47
▸ DAO P14920 2/20 0.47
▸ SRD5A2 P31213 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ BRD4 O60885 1/20 0.47
▸ DDO Q99489 1/20 0.47
▸ CA2 P00918 1/20 0.46
▸ RAB9A P51151 3/20 0.45
▸ NPC1 O15118 2/20 0.45
▸ LOXL2 Q9Y4K0 1/20 0.44
▸ CA12 O43570 1/20 0.43
▸ CA1 P00915 1/20 0.43
▸ CA3 P07451 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9620368 0.82 AOC3 (0.52) CHEK1KDRFLT3CYP2A6AOC3
SCHEMBL29694493 0.82 AOC3 (0.52) CHEK1KDRFLT3CYP2A6AOC3
SCHEMBL3769474 0.78 AOC3 (0.48) CHEK1KDRFLT3CYP2A6AOC3
SCHEMBL597869 0.78 AOC3 (0.48) CHEK1KDRFLT3CYP2A6AOC3
SCHEMBL2849094 0.78 AOC3 (0.48) CHEK1KDRFLT3CYP2A6AOC3
SCHEMBL723282 0.78 AOC3 (0.48) CHEK1KDRFLT3CYP2A6AOC3
SCHEMBL29763767 0.78 AOC3 (0.48) CHEK1KDRFLT3CYP2A6AOC3
SCHEMBL3809655 0.78 AOC3 (0.48) CHEK1KDRFLT3CYP2A6AOC3
Hydrochloric Acid SCHEMBL4591535 0.77 AOC3 (0.50) CHEK1KDRFLT3CYP2A6AOC3
Hydrochloric Acid SCHEMBL7697249 0.77 AOC3 (0.50) CHEK1KDRFLT3CYP2A6AOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3356387-B1 ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS UNIV MONASH (AU) 2024-06-26 — — EP claimed
US-11225505-B2 Antimicrobial polymyxin derivative compounds MONASH UNIVERSITY (AU) 2022-01-18 — — US claimed
US-10787484-B2 Compositions and methods for treating cardiovascular disease GENENTECH, INC. (US) 2020-09-29 — — US claimed
US-20190177366-A1 COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE GENENTECH, INC. (US) 2019-06-13 — — US claimed
EP-3474875-A1 COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE H. Hoffnabb-La Roche Ag (CH) 2019-05-01 — — EP claimed
US-20180282374-A1 ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS MONASH UNIVERSITY (AU) 2018-10-04 — — US claimed
EP-3356387-A1 ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS Monash University (AU) 2018-08-08 — — EP claimed
CN-107922428-A Thienopyrroles compound and its purposes as the inhibitor for piercing shrimp source property luciferase 普洛麦格公司 2018-04-17 — — CN claimed
EP-2758051-B1 CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS MERCK SHARP & DOHME (US) 2018-04-11 — — EP claimed
WO-2017220701-A1 COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2017-12-28 — — WO claimed
US-4885302-A 2-((4-Piperidyl)methyl)-1,2,3,4-tetrahydroisoquinoline derivatives, their preparation and their application in therapy SYNTHELABO, 58, RUE DE LA GLACIERE - 75013 PARIS 1989-12-05 — — US claimed
WO-1989007451-A1 REDUCED SIZE LHRH ANALOGS ABBOTT LABORATORIES (US) 1989-08-24 — — WO claimed
EP-0328089-A2 Reduced size LHRH analogs ABBOTT LABORATORIES (US) 1989-08-16 — — EP claimed
EP-0306375-A1 2-[(4-Piperidinyl)methyl]-1,2,3,4-tetrahydroisoquinoline derivatives, their preparation and their use in therapy SYNTHELABO (FR) 1989-03-08 — — EP claimed
US-4775747-A PIGMENTS FOR POLYMERS CIBA-GEIGY CORPORATION (US) 1988-10-04 — — US claimed
US-4727060-A HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1988-02-23 — — US claimed
EP-0099057-B1 N-ACYL DERIVATIVES OF PEPTIDES, THEIR MANUFACTURE AND USE IN COMBATING DISEASES AND MEANS THEREFOR BASF Aktiengesellschaft (DE) 1987-10-14 — — EP claimed
EP-0184550-A2 5-Amino-4-hydroxy valeryl amide derivatives CIBA-GEIGY AG (CH) 1986-06-11 — — EP claimed
EP-0053893-B1 DERIVATIVES OF CLAVULANIC ACID, THEIR PREPARATION AND THEIR USE BEECHAM GROUP PLC (GB) 1985-03-20 — — EP claimed
EP-0099057-A2 N-acyl derivatives of peptides, their manufacture and use in combating diseases and means therefor BASF Aktiengesellschaft (DE) 1984-01-25 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11225505-B2 Antimicrobial polymyxin derivative compounds VIP, PNKP, PEPD CHEK1 4367/4885KDR 2870/4885FLT3 1197/4885
US-20180282374-A1 ANTIMICROBIAL POLYMYXIN DERIVATIVE COMPOUNDS VIP, PNKP, PEPD CHEK1 4367/4885KDR 2870/4885FLT3 1197/4885
US-10787484-B2 Compositions and methods for treating cardiovascular disease PCSK9, PCSK7, PCSK6 CHEK1 3133/4885KDR 1228/4885FLT3 1892/4885
US-20190177366-A1 COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE PCSK9, PCSK7, PCSK6 CHEK1 3133/4885KDR 1228/4885FLT3 1892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.